{"id":"placebo-matching-metformin-xr","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL494397","moleculeType":"Small molecule","molecularWeight":"165.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo matching Metformin XR contains no active pharmaceutical ingredient and serves as a blinded control comparator in phase 3 trials. It is formulated to be indistinguishable from the active Metformin XR drug in terms of appearance, taste, and release characteristics, enabling proper randomized controlled trial design. This allows researchers to isolate the true effects of Metformin XR from placebo effects.","oneSentence":"This is a placebo formulation designed to match the appearance and administration profile of Metformin XR for use as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:56.438Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials of Metformin XR"}]},"trialDetails":[{"nctId":"NCT05093959","phase":"PHASE2","title":"Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-01-04","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":86},{"nctId":"NCT02915198","phase":"PHASE4","title":"Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-04-03","conditions":"Prediabetic State, Atherosclerosis, Metformin","enrollment":7410},{"nctId":"NCT05243654","phase":"PHASE2","title":"Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy","status":"RECRUITING","sponsor":"Oxford University Clinical Research Unit Indonesia","startDate":"2022-10-01","conditions":"Leprosy, Leprosy, Multibacillary, Neglected Tropical Diseases","enrollment":166},{"nctId":"NCT05900466","phase":"PHASE2","title":"Metformin for Fibromyalgia Symptoms (INFORM Trial)","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-04-01","conditions":"Fibromyalgia Syndrome","enrollment":72},{"nctId":"NCT06096259","phase":"PHASE2","title":"Preventing Injured Knees From osteoArthritis: Severity Outcomes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-05-06","conditions":"Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear","enrollment":512},{"nctId":"NCT02932475","phase":"PHASE3","title":"Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-05-25","conditions":"Diabetes, Pregnancy","enrollment":831},{"nctId":"NCT04530747","phase":"PHASE1, PHASE2","title":"Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea","status":"TERMINATED","sponsor":"Pennington Biomedical Research Center","startDate":"2021-01-28","conditions":"Sleep Apnea, Obstructive","enrollment":16},{"nctId":"NCT04622111","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2020-05-27","conditions":"Healthy Volunteers","enrollment":68},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT01864174","phase":"PHASE4","title":"Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":1736},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01814748","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05-03","conditions":"Diabetes Mellitus","enrollment":203},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT02004886","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08-11","conditions":"Type 2 Diabetes Mellitus","enrollment":74},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT01809327","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06-04","conditions":"Diabetes Mellitus, Type 2","enrollment":1186},{"nctId":"NCT01076088","phase":"PHASE3","title":"Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-15","conditions":"Type 2 Diabetes Mellitus","enrollment":744},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT00859898","phase":"PHASE3","title":"Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":1093},{"nctId":"NCT00087516","phase":"PHASE3","title":"Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":741},{"nctId":"NCT00918138","phase":"PHASE3","title":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT00951899","phase":"PHASE4","title":"The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":38},{"nctId":"NCT00443755","phase":"PHASE2","title":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-08","conditions":"Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome","enrollment":28},{"nctId":"NCT01023581","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":784}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching Metformin XR","genericName":"Placebo matching Metformin XR","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match the appearance and administration profile of Metformin XR for use as a control in clinical trials. Used for Control arm in phase 3 clinical trials of Metformin XR.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}